Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Oct 2020
Historique:
received: 13 03 2020
revised: 23 04 2020
accepted: 27 04 2020
pubmed: 4 5 2020
medline: 15 5 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

The prognostic role of diabetes mellitus (DM) in heart failure (HF) patients is undefined, since DM is outweighed by several DM-related variables when confounders are considered. We determined the prognostic role of DM, treatment, and glycemic control in a real-life HF population. 3927 HF patients included in the Metabolic Exercise Cardiac Kidney Index (MECKI) score database were evaluated with a median follow-up of 3.66 years (IQR 1.70-6.67). Data analysis considered survival between DM (n = 897) vs. non-DM (n = 3030) patients, and, in diabetics, between insulin (n = 304), oral antidiabetics (n = 479), and dietary only (n = 88) treatments. The role of glycemic control was evaluated grouping DM patients according to glycated hemoglobin (HbA1c): <7% (n = 266), 7.1-8% (n = 133), >8% (n = 149). All analyses were performed also adjusting for ejection fraction, renal function, hemoglobin, sodium, exercise peak oxygen uptake, and ventilation/carbon dioxide relationship slope. Study primary endpoint was the composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Secondary endpoints were cardiovascular and all causes death. For all endpoints, upon adjustment for confounders, DM status and insulin treatment or dietary regimen were not significantly associated with adverse long-term prognosis compared to non-DM and oral antidiabetic treated patients, respectively. A worse prognosis was observed in HbA1c >8% patients (Log-Rank p < 0.001), even after correction for confounding factors. All results were replicated by hazard ratio analysis. In HF patients, DM, insulin treatment and dietary regimen are not adverse outcome predictors. The only condition related to long-term prognosis, considering potential confounders, is poor glycemic control.

Sections du résumé

BACKGROUND BACKGROUND
The prognostic role of diabetes mellitus (DM) in heart failure (HF) patients is undefined, since DM is outweighed by several DM-related variables when confounders are considered. We determined the prognostic role of DM, treatment, and glycemic control in a real-life HF population.
METHODS METHODS
3927 HF patients included in the Metabolic Exercise Cardiac Kidney Index (MECKI) score database were evaluated with a median follow-up of 3.66 years (IQR 1.70-6.67). Data analysis considered survival between DM (n = 897) vs. non-DM (n = 3030) patients, and, in diabetics, between insulin (n = 304), oral antidiabetics (n = 479), and dietary only (n = 88) treatments. The role of glycemic control was evaluated grouping DM patients according to glycated hemoglobin (HbA1c): <7% (n = 266), 7.1-8% (n = 133), >8% (n = 149). All analyses were performed also adjusting for ejection fraction, renal function, hemoglobin, sodium, exercise peak oxygen uptake, and ventilation/carbon dioxide relationship slope. Study primary endpoint was the composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Secondary endpoints were cardiovascular and all causes death.
RESULTS RESULTS
For all endpoints, upon adjustment for confounders, DM status and insulin treatment or dietary regimen were not significantly associated with adverse long-term prognosis compared to non-DM and oral antidiabetic treated patients, respectively. A worse prognosis was observed in HbA1c >8% patients (Log-Rank p < 0.001), even after correction for confounding factors. All results were replicated by hazard ratio analysis.
CONCLUSION CONCLUSIONS
In HF patients, DM, insulin treatment and dietary regimen are not adverse outcome predictors. The only condition related to long-term prognosis, considering potential confounders, is poor glycemic control.

Identifiants

pubmed: 32360652
pii: S0167-5273(20)31266-3
doi: 10.1016/j.ijcard.2020.04.079
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-110

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no relationships that could be construed as a conflict of interest.

Auteurs

Stefania Paolillo (S)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy; Mediterranea Cardiocentro, Naples, Italy.

Elisabetta Salvioni (E)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Pasquale Perrone Filardi (P)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy.

Alice Bonomi (A)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Gianfranco Sinagra (G)

Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy.

Piero Gentile (P)

Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy.

Paola Gargiulo (P)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy.

Alessandra Scoccia (A)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Nicola Cosentino (N)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Paola Gugliandolo (P)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Roberto Badagliacca (R)

Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, "Sapienza", Rome University, Rome, Italy.

Rocco Lagioia (R)

Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy.

Michele Correale (M)

Department of Cardiology, University of Foggia, Foggia, Italy.

Maria Frigerio (M)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda- A.O. Niguarda, Milano, Italy.

Enrico Perna (E)

Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda- A.O. Niguarda, Milano, Italy.

Massimo Piepoli (M)

UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy.

Federica Re (F)

Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Roma, Italy.

Rosa Raimondo (R)

Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Tradate, Italy.

Chiara Minà (C)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy.

Francesco Clemenza (F)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy.

Maurizio Bussotti (M)

Unità Operativa Cardiologia Riabilitativa, Multimedica IRCCS, Milano, Italy.

Giuseppe Limongelli (G)

Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy.

Rita Gravino (R)

Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy.

Andrea Passantino (A)

Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy.

Damiano Magrì (D)

Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Roma, Italy.

Gianfranco Parati (G)

Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.; San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy.

Sergio Caravita (S)

San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy.; Department of Management, Information and Production Engineering, University of Bergamo, Dalmine (BG), Italy.

Angela B Scardovi (AB)

Cardiology Division, Santo Spirito Hospital, Roma, Italy.

Luca Arcari (L)

Cardiology Division, Santo Spirito Hospital, Roma, Italy.

Carlo Vignati (C)

Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical Sciences and Community health, Cardiovascular Section, University of Milano, Milano, Italy.

Massimo Mapelli (M)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Gaia Cattadori (G)

Unità Operativa Cardiologia Riabilitativa, Multimedica IRCCS, Milano, Italy.

Carlo Cavaliere (C)

IRCCS SDN, Napoli, Italy.

Ugo Corrà (U)

Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Veruno, Italy.

Piergiuseppe Agostoni (P)

Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical Sciences and Community health, Cardiovascular Section, University of Milano, Milano, Italy.. Electronic address: piergiuseppe.agostoni@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH